Melissa Alsina
About
Melissa Alsina is a scholar working on Hematology, Molecular Biology and Oncology.
According to data from OpenAlex, Melissa Alsina has authored 221 papers receiving a total of 6.7k indexed citations (citations by other indexed papers that have themselves been cited), including 177 papers in Hematology, 119 papers in Molecular Biology and 103 papers in Oncology. Recurrent topics in Melissa Alsina's work include Multiple Myeloma Research and Treatments (152 papers), Protein Degradation and Inhibitors (74 papers) and Cancer Treatment and Pharmacology (39 papers). Melissa Alsina is often cited by papers focused on Multiple Myeloma Research and Treatments (152 papers), Protein Degradation and Inhibitors (74 papers) and Cancer Treatment and Pharmacology (39 papers). Melissa Alsina collaborates with scholars based in United States, Canada and France. Melissa Alsina's co-authors include Paul G. Richardson, Sundar Jagannath, Kenneth C. Anderson, David S. Siegel, William S. Dalton, Sun Jin Choi, G. David Roodman, James R. Berenson, David Irwin and Kenneth H. Shain and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
Melissa Alsina
215 papers receiving 6.5k citations
Hit Papers
Peers
Melissa Alsina
Natalie S. Callander United States
Laura Rosiñol Spain
Suzanne Lentzsch United States
Peter M. Voorhees United States
Martin Kaiser United Kingdom
Bruno Paiva Spain
Carla S. Wilson United States
Robert Vescio United States
Norma C. Gutiérrez Spain
Jean‐François Rossi France
Citations per year, relative to Melissa Alsina Melissa Alsina (= 1×)
peers
Natalie S. Callander
Countries citing papers authored by Melissa Alsina
Since
Specialization
Citations
This map shows the geographic impact of Melissa Alsina's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melissa Alsina with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melissa Alsina more than expected).
Fields of papers citing papers by Melissa Alsina
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Melissa Alsina. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melissa Alsina. The network helps show where Melissa Alsina may publish in the future.
Co-authorship network of co-authors of Melissa Alsina
This figure shows the co-authorship network connecting the top 25 collaborators of Melissa Alsina. A scholar is included among the top collaborators of Melissa Alsina based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melissa Alsina. Melissa Alsina is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Chari, Ajai, Susan Bal, Sikander Ailawadhi, et al.. (2025). Expert Perspectives on Current Challenges and Emerging Approaches for Multiple Myeloma: Narrative Review of an Inaugural Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 25(9). 635–645.
2.
Alsina, Melissa, Binod Dhakal, Jeremy Pantin, Carol Ann Huff, & Murali Janakiram. (2025). Establishing a successful outpatient CAR T-Cell program with cilta-cel: real-world experience from an expert roundtable. Future Oncology. 21(10). 1137–1144.
3.
Arnulf, Bertrand, Tessa Kerre, Mounzer Agha, et al.. (2024). Efficacy and safety of ciltacabtagene autoleucel ± lenalidomide maintenance in newly diagnosed multiple myeloma with suboptimal response to frontline autologous stem cell transplant: CARTITUDE-2 cohort D.. Journal of Clinical Oncology. 42(16_suppl). 7505–7505.
4.
Leleu, Xavier, Alfred Chung, Noopur Raje, et al.. (2024). P-045 Idecabtagene Vicleucel (ide-cel) in Patients (pts) With Clinical High-Risk Early Relapse Multiple Myeloma (MM) Without Front-Line (1L) Autologous Stem Cell Transplantation (ASCT): KarMMA-2 Cohort 2B. Clinical Lymphoma Myeloma & Leukemia. 24. S67–S67.
5.
Freeman, Ciara L., Meghan Menges, Hien Liu, et al.. (2023). Paired Analysis from Patients with Myeloma Elucidates Favorable CAR-T Manufacture and Phenotype, Starting from Mobilized Pre-Transplant Apheresis Vs. Non-Mobilized Apheresis after Four Prior Lines. Blood. 142(Supplement 1). 1931–1931.
6.
Freeman, Ciara L., Meghan Menges, Jeffrey Edelman, et al.. (2023). Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma. Clinical Cancer Research. 29(22). 4575–4585.
7.
Freeman, Ciara L., Xiaohong Zhao, Mark B. Meads, et al.. (2023). Single Cell RNA Sequencing of Sequential Samples before and after BCMA-Directed CAR-T Reveal Features Associated with Non-Durable Response, Exhausted T-Cells and Decreased Expression of Genes Encoding Key Surface Targets in Particular in Patients with Extramedullary Disease. Blood. 142(Supplement 1). 3304–3304.
8.
Bashir, Qaiser, Taiga Nishihori, Marcelo C. Pasquini, et al.. (2022). A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial. Transplantation and Cellular Therapy. 29(6). 358.e1–358.e7.
9.
Raje, Noopur, Nina Shah, Sundar Jagannath, et al.. (2021). Updated Clinical and Correlative Results from the Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma. Blood. 138(Supplement 1). 548–548.
10.
Shah, Nina, Melissa Alsina, David S. Siegel, et al.. (2018). Initial Results from a Phase 1 Clinical Study of bb21217, a Next-Generation Anti Bcma CAR T Therapy. Blood. 132(Supplement 1). 488–488.
11.
Baz, Rachid, Jeffrey A. Zonder, Kenneth H. Shain, et al.. (2017). Phase I/II Study of Liposomal Doxorubicin (DOX) in Combination with Selinexor (SEL) and Dexamethasone (Dex) for Relapsed and Refractory Multiple Myeloma (RRMM). Blood. 130. 3095–3095.
12.
Salem, Karma Z., Taiga Nishihori, Mohamed A. Kharfan‐Dabaja, Pedro Horna, & Melissa Alsina. (2015). Primary plasmacytoma involving mediastinal lymph nodes. Hematology/Oncology and Stem Cell Therapy. 9(1). 26–29.
13.
Baz, Rachid, Hui‐Yi Lin, Sung‐Soo Yoon, et al.. (2013). Response Adapted Lenalidomide Based Therapy For Newly Diagnosed (ND) Standard Risk Older Adults With Multiple Myeloma (MM): An International Collaboration. Blood. 122(21). 3201–3201.
14.
Boucher, Kelly, Raymond Widen, Kenneth H. Shain, et al.. (2012). Stemness of B-cell Progenitors in Multiple Myeloma Bone Marrow. Clinical Cancer Research. 18(22). 6155–6168.
15.
Alsina, Melissa, Suzanne Trudel, Richard R. Furman, et al.. (2012). A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma. Clinical Cancer Research. 18(17). 4830–4840.
16.
Nishihori, Taiga, Mohamed A. Kharfan‐Dabaja, José L. Ochoa-Bayona, et al.. (2011). Role of reduced intensity conditioning in allogeneic hematopoietic cell transplantation for patients with multiple myeloma. Hematology/Oncology and Stem Cell Therapy. 4(1). 1–9.
17.
Richardson, Paul G., Asher Chanan‐Khan, Melissa Alsina, et al.. (2010). Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose‐escalation study. British Journal of Haematology. 150(4). 438–445.
18.
Yarde, Danielle N., Vasco Oliveira, Linda Mathews, et al.. (2009). Targeting the Fanconi Anemia/BRCA Pathway Circumvents Drug Resistance in Multiple Myeloma. Cancer Research. 69(24). 9367–9375.
19.
Choi, Sun Jin, Yasuo Oba, Yair Gazitt, et al.. (2001). Antisense inhibition of macrophage inflammatory protein 1-α blocks bone destruction in a model of myeloma bone disease. Journal of Clinical Investigation. 108(12). 1833–1841.
20.
Gazitt, Yair, César O. Freytes, Natalie S. Callander, et al.. (1999). Successful PBSC Mobilization with High-Dose G-CSF for Patients Failing a First Round of Mobilization. Journal of Hematotherapy. 8(2). 173–183.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Natalie S. Callander Breakdown of academic impact, for papers by Laura Rosiñol Breakdown of academic impact, for papers by Suzanne Lentzsch Breakdown of academic impact, for papers by Peter M. Voorhees Breakdown of academic impact, for papers by Martin Kaiser Breakdown of academic impact, for papers by Bruno Paiva Breakdown of academic impact, for papers by Carla S. Wilson Breakdown of academic impact, for papers by Robert Vescio Breakdown of academic impact, for papers by Norma C. Gutiérrez Breakdown of academic impact, for papers by Jean‐François Rossi